Maravai LifeSciences
Offers oligonucleotide synthesis and immunohistochemistry
Manager QA Operations
About the job
- A bachelor's degree in Life Science, Biology, Chemistry, Pharmaceutical, or a related discipline is required.
- Three to five years of managerial experience in a non-academic biotechnology-related industry is required.
- One to three years of supervisory experience is required.
- Proven experience with ISO 13485 certification, federal regulation 21 CFR 820, and 21 CFR Part 11 is required.
- Thorough knowledge of analytical testing industry standards and quality assurance methodologies is required.
- Excellent communication and presentation skills are required.
- Demonstrated scientific problem-solving skills translated into a consultative selling process are required.
- Ability to participate with others as a team member to handle demanding and difficult projects smoothly and cooperatively is required.
- Proven ability to thrive in a startup and change-oriented environment is required.
- Great attention to detail and a results-driven approach are required.
- Ability to organize and prioritize a diverse set of responsibilities is required.
- Proven coaching, mentoring, team-building, and leadership skills are required.
- Manage Quality Assurance department day-to-day operations, including implementing training and performance management activities for direct reports.
- Implement and periodically evaluate documentation and policies to ensure continuous compliance with organizational standards, ISO 13485:2016, and statutory and regulatory requirements.
- Collaborate with management to identify and fill documentation and process gaps required to maintain Quality Management System compliance and address corrective and preventive actions, nonconformances, and audit findings.
- Author and maintain quality documentation and oversee timely reviews of work instructions associated with production and quality control activities.
- Support Quality Control with customer complaints and out-of-specification investigations.
- Participate on core teams and provide Quality Assurance deliverables for quality processes and documentation practices from production through testing and shipment.
- Implement and track metrics to monitor Quality Management performance.
- Identify and implement efficiency improvement initiatives supporting continuous improvement.
- Facilitate proactive solutions by collecting and analyzing quality data.
- Manage the Internal Audit Program.
- Perform other required functions and duties.
- Industry experience in a Good Manufacturing Practice environment is preferred.
About the company
Maravai LifeSciences provides tools and services for life sciences research and bioproduction, including supplying oligonucleotides for PCR, next-generation sequencing (NGS), and gene editing, as well as immunohistochemistry for cancer research, serving academic institutions, biotechnology firms, and pharmaceutical companies. Oligonucleotide synthesis creates short DNA or RNA strands used in PCR, sequencing, and genome editing workflows; immunohistochemistry uses labeled antibodies to detect proteins in tissue samples. It differentiates itself by combining investment and operational support to incubate and scale life science companies while offering essential research tools. Its goal is to catalyze the development of life science companies to advance human health by providing capital, expertise, and essential research tools.
Company Size
51-200
Company Stage
IPO
Headquarters
San Diego, California
Founded
2014
Get referred to Maravai LifeSciences
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue reached $51.4 million, with TriLink up 11.5% and Cygnus growing.
- Management raised 2026 adjusted EBITDA guidance to $33 million-$35 million on August 6.
- Base TriLink revenue grew 13.4% in first-half 2026, excluding COVID CleanCap orders.
What critics are saying
- March 2025 securities litigation over revenue recognition keeps internal-controls failures in focus.
- Q1 2026 growth still leaned on $14.3 million in COVID CleanCap orders.
- August 2025 layoffs cut 25% of staff, signaling fragile demand and execution risk.
What makes Maravai LifeSciences unique
- TriLink and Cygnus sell mission-critical reagents embedded in regulated biomanufacturing workflows.
- Maravai’s 2026 balance sheet strengthened after June refinancing, extending debt maturity to 2032.
- The company combines discovery, GMP consumables, and assay kits across genomics and biotherapeutics.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Company Equity
Fertility Treatment Support
Family Planning Benefits
401(k) Retirement Plan
Paid Vacation
Growth & Insights and Company News
6 month growth
↓ -3%1 year growth
↓ -3%2 year growth
↓ -3%Maravai LifeSciences (NASDAQ:MRVI) sets new 52-week high - still a Buy? August 25, 2026 Key points. * Maravai LifeSciences shares hit a new 52-week high, reaching $8.87 and closing around $8.75, up 3.3% on the session. The stock's market capitalization is approximately $2.26 billion. * Analyst sentiment remains mixed, with two Buy and two Sell ratings producing a consensus "Hold" rating and a $6.25 price target - well below the current share price. * Maravai exceeded quarterly expectations, reporting an adjusted loss of $0.02 per share versus the expected $0.04 loss and revenue of $51.44 million versus estimates of $48.67 million. However, the company remains unprofitable, with negative margins and analysts forecasting a full-year loss. * Five stocks to consider instead of Maravai LifeSciences. Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report)'s share price reached a new 52-week high during trading on Tuesday. The stock traded as high as $8.87 and last traded at $8.7450, with a volume of 1027230 shares traded. The stock had previously closed at $8.43. Analyst upgrades and downgrades. Several equities analysts have weighed in on MRVI shares. Weiss Ratings upgraded Maravai LifeSciences from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, May 29th. UBS Group reissued a "reduce" rating on shares of Maravai LifeSciences in a report on Wednesday, June 3rd. Deutsche Bank Aktiengesellschaft reissued a "buy" rating and issued a $6.00 price objective on shares of Maravai LifeSciences in a research note on Friday, May 8th. Wall Street Zen raised Maravai LifeSciences from a "hold" rating to a "buy" rating in a research report on Saturday, August 15th. Finally, Wells Fargo & Company increased their price target on Maravai LifeSciences from $5.50 to $6.50 and gave the company an "overweight" rating in a report on Friday, August 7th. Two research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $6.25. Maravai LifeSciences trading up 3.3%. The company has a market capitalization of $2.26 billion, a price-to-earnings ratio of -16.76 and a beta of 0.63. The company has a 50-day moving average price of $6.35 and a 200-day moving average price of $4.62. The company has a quick ratio of 2.98, a current ratio of 4.05 and a debt-to-equity ratio of 0.49. Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.02. The business had revenue of $51.44 million during the quarter, compared to analysts' expectations of $48.67 million. Maravai LifeSciences had a negative return on equity of 15.70% and a negative net margin of 37.07%. Research analysts predict that Maravai LifeSciences Holdings, Inc. will post -0.2 EPS for the current fiscal year. Insider buying and selling at Maravai LifeSciences. In other news, General Counsel Kurt Oreshack sold 25,000 shares of the firm's stock in a transaction on Tuesday, June 9th. The shares were sold at an average price of $5.06, for a total value of $126,500.00. Following the sale, the general counsel owned 360,767 shares in the company, valued at approximately $1,825,481.02. This trade represents a 6.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 2.49% of the company's stock. Institutional trading of Maravai LifeSciences. A number of hedge funds have recently bought and sold shares of MRVI. Jane Street Group LLC increased its holdings in shares of Maravai LifeSciences by 1,463.1% during the 1st quarter. Jane Street Group LLC now owns 380,403 shares of the company's stock worth $841,000 after purchasing an additional 356,067 shares during the period. Creative Planning grew its position in Maravai LifeSciences by 49.6% during the second quarter. Creative Planning now owns 116,031 shares of the company's stock worth $280,000 after buying an additional 38,450 shares in the last quarter. Rhumbline Advisers grew its position in Maravai LifeSciences by 20.3% during the second quarter. Rhumbline Advisers now owns 195,272 shares of the company's stock worth $471,000 after buying an additional 32,940 shares in the last quarter. Prudential Financial Inc. bought a new position in Maravai LifeSciences during the second quarter valued at about $36,000. Finally, Invesco Ltd. increased its stake in Maravai LifeSciences by 16.8% during the second quarter. Invesco Ltd. now owns 282,192 shares of the company's stock valued at $680,000 after acquiring an additional 40,495 shares during the period. 50.25% of the stock is owned by institutional investors. Maravai LifeSciences company profile. Maravai LifeSciences Holdings, Inc NASDAQ: MRVI is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company's offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai's platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry. Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Maravai LifeSciences, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maravai LifeSciences wasn't on the list. While Maravai LifeSciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. Enter your email address and we'll send you MarketBeat's list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today anno...
SAN DIEGO, Calif., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of…...
The selling stockholders named in this prospectus are offering 20,000,000 shares of our Class A common stock. We are not selling any shares under this prospectus and we will not receive any proceeds from the sale of shares by the selling stockholders.
Maravai LifeSciences has refinanced its credit agreement, securing a $150 million term loan facility and a $30 million revolving credit facility. The life science reagents provider used the new term loan borrowings and approximately $98.5 million in cash to prepay its existing credit agreement due in October 2027. The transaction reduces Maravai's long-term debt from $242.9 million to $150 million and extends the maturity date to June 2032. Chief Financial Officer Raj Asarpota said the refinancing strengthens the company's financial foundation whilst preserving capital access for strategic priorities and growth initiatives. Maravai provides critical products for drug therapy development, diagnostics and vaccine research, serving major biopharmaceutical, vaccine and cell and gene therapy companies globally.